HOME >> BIOLOGY >> NEWS
New role in asthma for old drug

The results of a study in mice by researchers from Erasmus University, The Netherlands, have indicated that an inhaled drug currently used to treat individuals with pulmonary arterial hypertension (raised blood pressure in the blood vessels in the lungs that leads to shortness of breath, dizziness, and fainting) might provide a new therapeutic to treat individuals with asthma.

Iloprost is a stable analog of the naturally occurring soluble factor PGI2. It is used to treat pulmonary arterial hypertension because it causes blood vessels to widen, thereby increasing blood flow and reducing blood pressure. However, recent studies have indicated that PGI2, and therefore iloprost, might also have anti-inflammatory properties. In a study that appears in the February issue of the Journal of Clinical Investigation, Bart Lambrecht and colleagues show that inhalation of iloprost inhibits the Th2 cell inflammatory response that causes disease in a mouse model of allergic asthma. Inhalation of iloprost inhibited this response in two ways. First, it prevented the immune cells in the lungs that activate the Th2 cell response (known as dendritic cells [DCs]) from leaving the lungs and going to the site at which they activate the allergic Th2 cell response. Second, it blocked the DCs becoming activated enough to stimulate an allergic Th2 cell response. This study therefore indicates that targeting DCs in the lungs can suppress allergic asthma in mice and might lead to studies determining whether such targeting by iloprost can provide a new treatment for individuals with asthma.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
1-Feb-2007


Page: 1

Related biology news :

1. Crystal structure enables tailoring of pharmaceuticals against asthma
2. New asthma gene could lead to new therapies
3. Book explores history, causes of allergy and asthma epidemic
4. Coarse particulate matter in air may harm hearts of asthma sufferers, UNC study finds
5. A new study links a stomach microbe to asthma prevention
6. Apple consumption during pregnancy reduces risk for childhood wheezing and asthma
7. Cincinnnati scientists pursue new target for asthma treatment
8. Potential new therapeutic target for asthma, allergies and cancer
9. Allergy/asthma and cystic fibrosis (CF) focus of awareness in May
10. A new view of asthmas cause
11. Women pregnant with girls experience more severe asthma symptoms

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2018)... (PRWEB) , ... August 07, 2018 , ... CallTower ... today their new CT Cloud Voice and SIP solutions. CT Cloud solutions are ... secure, quality voice solution that is far superior to traditional PBX systems, at a ...
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder ... winning recipients of the 2018 IAC Awards at the 23rd World Congress on Heart ... also named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, ...
(Date:8/1/2018)... , ... August 01, 2018 , ... Visikol CEO Dr. ... services and strong pharmaceutical company partnerships that Visikol will far exceed its original 2018 ... developing its suite of digital pathology tools, whole mount imaging ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ... was developed and is continually updated by a talented scientific team that includes ... service provides: , 1. Information on the medical impact of a patient’s ...
(Date:8/9/2018)... ... August 09, 2018 , ... Simpson ... construction (AEC) experts with building owners and managers for a full-day discussion on ... Construct symposium comes to Boston for the first time on Thursday, 13 September ...
(Date:7/31/2018)... (PRWEB) , ... July 31, 2018 , ... ... 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product inventory. ... controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an evidence-based ... combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers for ... was reported:, Over 70% decrease in Interleukin (IL-1ß) ...
Breaking Biology Technology:
Cached News: